-
Johnson & Johnson (JNJ $156.90)
-
Eli Lilly and Company (LLY $793.01)
-
Merck & Company Inc. (MRK $83.36)
Q: One gets weary of the seemingly endless legal battles that JNJ continues to suffer. I have held on to shares assuming all sides would surely give in to battle-fatigue. My assumption looks wrong, especially after yet another defeat by JNJ on Friday July 28. Worth holding or move on? As always, your opinion backed by your own reasoning would be much appreciated. If you think best trim or sell, what dividend payer in health care would you favor today (US only).